Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 26

Sort by

Sort Order Select

Journal Articles

The growing landscape of FLT3 inhibition in AML

Catherine C. Smith

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 539–547.

https://doi.org/10.1182/hematology.2019000058

Published: 2019

Journal Articles

MRD evaluation of AML in clinical practice: are we there yet?

Sylvie D. Freeman, Christopher S. Hourigan

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 557–569.

https://doi.org/10.1182/hematology.2019000060

Published: 2019

Journal Articles

Evidence-Based Minireview: Longitudinal geriatric assessment in quality care for older patients with hematologic malignancies

Richard J. Lin, Heidi D. Klepin

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 59–62.

https://doi.org/10.1182/hematology.2019000076

Published: 2019

Journal Articles

When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter

Gregory W. Roloff, Elizabeth A. Griffiths

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 35–44.

https://doi.org/10.1182/asheducation-2018.1.35

Published: 2018

Journal Articles

Cytotoxic therapy in acute myeloid leukemia: not quite dead yet

Laura C. Michaelis

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 51–62.

https://doi.org/10.1182/asheducation-2018.1.51

Published: 2018

Journal Articles

The role of targeted therapy in the management of patients with AML

Alexander E. Perl

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 54–65.

https://doi.org/10.1182/asheducation-2017.1.54

Published: 2017

Journal Articles

Mutations in AML: prognostic and therapeutic implications

Courtney D. DiNardo, Jorge E. Cortes

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 348–355.

https://doi.org/10.1182/asheducation-2016.1.348

Published: 2016

Journal Articles

MRD in AML: does it already guide therapy decision-making?

Gert Ossenkoppele, Gerrit Jan Schuurhuis

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 356–365.

https://doi.org/10.1182/asheducation-2016.1.356

Published: 2016

Journal Articles

Molecularly targeted therapies for acute myeloid leukemia

Eytan M. Stein

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 579–583.

https://doi.org/10.1182/asheducation-2015.1.579

Published: 2015

Journal Articles

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults

Mohamed L. Sorror, Elihu Estey

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 21–33.

https://doi.org/10.1182/asheducation-2014.1.21

Published: 2014

Journal Articles

Intermediate-risk acute myeloid leukemia therapy: current and future

Konstanze Döhner, Peter Paschka

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 34–43.

https://doi.org/10.1182/asheducation.V2014.1.34.3882398

Published: 2014

Journal Articles

Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?

Peter Paschka, Konstanze Döhner

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 209–219.

https://doi.org/10.1182/asheducation-2013.1.209

Published: 2013

Journal Articles

FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

Mark Levis

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 220–226.

https://doi.org/10.1182/asheducation-2013.1.220

Published: 2013

Journal Articles

The prevalent predicament of relapsed acute myeloid leukemia

Jeffrey Szer

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 43–48.

https://doi.org/10.1182/asheducation.V2012.1.43.3798183

Published: 2012

Journal Articles

Impact of Genetic Features on Treatment Decisions in AML

Hartmut Döhner, Verena I. Gaidzik

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 36–42.

https://doi.org/10.1182/asheducation-2011.1.36

Published: 2011

Journal Articles

High Cytogenetic or Molecular Genetic Risk Acute Myeloid Leukemia

Elihu Estey

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 474–480.

https://doi.org/10.1182/asheducation-2010.1.474

Published: 2010

Journal Articles

New Prognostic Markers in Acute Myeloid Leukemia: Perspective from the Clinic

James M. Foran

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 47–55.

https://doi.org/10.1182/asheducation-2010.1.47

Published: 2010

Journal Articles

ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse?

Monica S. Thakar, Stephen J. Forman

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 414–418.

https://doi.org/10.1182/asheducation-2009.1.414

Published: 2009

Journal Articles

Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia

Torsten Haferlach

Hematology Am Soc Hematol Educ Program (2008) 2008 (1): 400–411.

https://doi.org/10.1182/asheducation-2008.1.400

Published: 2008

Journal Articles

Targeting Treatment in AML

Alan K. Burnett, Steve Knapper

Hematology Am Soc Hematol Educ Program (2007) 2007 (1): 429–434.

https://doi.org/10.1182/asheducation-2007.1.429

Published: 2007

NARROW

The growing landscape of FLT3 inhibition in AML

MRD evaluation of AML in clinical practice: are we there yet?

Evidence-Based Minireview: Longitudinal geriatric assessment in quality care for older patients with hematologic malignancies

When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter

Cytotoxic therapy in acute myeloid leukemia: not quite dead yet

The role of targeted therapy in the management of patients with AML

Mutations in AML: prognostic and therapeutic implications

MRD in AML: does it already guide therapy decision-making?

Molecularly targeted therapies for acute myeloid leukemia

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults

Intermediate-risk acute myeloid leukemia therapy: current and future

Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?

FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

The prevalent predicament of relapsed acute myeloid leukemia

Impact of Genetic Features on Treatment Decisions in AML

High Cytogenetic or Molecular Genetic Risk Acute Myeloid Leukemia

New Prognostic Markers in Acute Myeloid Leukemia: Perspective from the Clinic

ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse?

Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia

Targeting Treatment in AML

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only